Previous reports support the notion that the tight interplay between deregulated EVI1 and simultaneous disturbances in the dosage of other myeloid TFs, such as GATA2, is linked to the development and maintenance of therapy-resistant AML with 3q26.2/EVI1 rearrangements [16–18, 20]. Here, MECOM is linked to acute myeloid leukemia.